Comparative Pharmacology
Head-to-head clinical analysis: TIVICAY PD versus VIRAC REX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TIVICAY PD versus VIRAC REX.
TIVICAY PD vs VIRAC REX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tivicay PD (dolutegravir) is an HIV-1 integrase strand transfer inhibitor (INSTI) that inhibits the catalytic activity of HIV-1 integrase, preventing the integration of viral DNA into host chromosomal DNA, which is essential for viral replication.
VirAcRex is a direct-acting antiviral that inhibits the viral RNA-dependent RNA polymerase (NS5B) by acting as a chain terminator, thereby blocking viral replication.
50 mg orally once daily, with or without food.
300 mg orally once daily with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 12-15 hours in adults, supporting once-daily dosing.
Terminal elimination half-life: 2.5-3.5 hours; clinical context: requires thrice-daily dosing to maintain therapeutic levels.
Primarily metabolized by UGT1A1 with minor CYP3A4; 53% of dose recovered in feces (30% as unchanged drug) and 31% in urine (18% as unchanged drug).
Renal: 30-40% unchanged; biliary/fecal: 50-60% as metabolites; <10% in feces as parent drug.
Category C
Category C
Antiretroviral, integrase inhibitor
Antiretroviral